News Search Results

Displaying Results 401-425 of 819 "cns"

Apr 29, 2025, 10:05 ET Active Pharmaceutical Ingredients (API) Market to Amass $359.45 Billion by 2030 at CAGR 5.85% - Grand View Research, Inc.

Ingredients Market - Application Outlook (Revenue, USD Billion, 2018 - 2030) Cardiovascular DiseasesOncologyCNS and NeurologyOrthopedicEndocrinologyPulmonologyGastroenterologyNephrologyOphthalmologyOthersActive

More news about: Grand View Research, Inc.


Apr 29, 2025, 07:00 ET Corero Network Security Wins 2025 Global InfoSec Award for "Best Service for a DDoS Protection Solution"

Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial-of-service (DDoS) protection specialists, today announced it has been named "Best Service for a DDoS Protection

More news about: Corero Network Security


Apr 28, 2025, 20:05 ET INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA

oncology, diabetes, central nervous system ("CNS") disorders, and B-cell-mediated autoimmune diseases. The Company's product candidates include, among others, SC291 for the treatment of, inter alia, B-cell malignancies; SC379 for the treatment of certain CNS disorders; and SG299, which is part of

More news about: Pomerantz LLP


Apr 28, 2025, 18:23 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)

https://www.cohenandsteers.com  Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,

More news about: Cohen & Steers, Inc.


Apr 28, 2025, 18:07 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)

https://www.cohenandsteers.com/Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,

More news about: Cohen & Steers, Inc.


Apr 28, 2025, 18:07 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)

https://www.cohenandsteers.com  Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,

More news about: Cohen & Steers, Inc.


Apr 28, 2025, 18:05 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)

https://www.cohenandsteers.com/Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,

More news about: Cohen & Steers, Inc.


Apr 28, 2025, 18:04 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)

https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,

More news about: Cohen & Steers, Inc.


Apr 28, 2025, 14:35 ET Late-Breaking Research from SK Life Science Labs at AACR Annual Meeting Shows p300-Selective Degraders are Potent Growth Inhibitors in Models of Aggressive Prostate Cancers and Solid Tumors

Biopharmaceuticals Co., Ltd., a global biotech focused on the research, development, and commercialization of treatments for disorders of the central nervous system (CNS) and cancer, presented late-breaking research at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago.

More news about: SK Life Science Labs


Apr 28, 2025, 14:15 ET INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA

oncology, diabetes, central nervous system ("CNS") disorders, and B-cell-mediated autoimmune diseases.  The Company's product candidates include, among others, SC291 for the treatment of, inter alia, B-cell malignancies; SC379 for the treatment of certain CNS disorders; and SG299, which is part of

More news about: Pomerantz LLP


Apr 28, 2025, 13:43 ET ABRINT GLOBAL CONGRESS 2025: TECHENABLER MOSTRA PROTEÇÃO HÍBRIDA CONTRA OS ATAQUES DE NEGAÇÃO DE SERVIÇO DESTINADA A OPERADORAS E ISPS DE QUALQUER TAMANHO

Edimburgo, no Reino Unido, a Corero está sediada em Londres e listada nos mercados AIM da Bolsa de Valores de Londres (ticker: CNS) e US OTCQX Market (OTCQX: DDOSF). Para mais informações, visite www.corero.com ou

More news about: TechEnabler


Apr 28, 2025, 08:00 ET Celltrion to present six abstracts in inflammatory bowel disease (IBD) at 2025 Digestive Disease Week® (DDW)

NEUROLOGIC REACTIONS Agents that inhibit TNF have been associated with central nervous system (CNS) manifestation of systemic vasculitis, seizure and new onset or exacerbation of CNS demyelinating disorders, including multiple sclerosis and optic neuritis and peripheral demyelinating disorders,

More news about: Celltrion


Apr 27, 2025, 22:00 ET 2025 AACR | Abbisko Therapeutics Presents Late-Breaking Pre-clinical Research Results on ABSK112 (EGFR exon20ins), ABSK131 (PRMT5*MTA), and ABK-KRAS-1

G12C inhibitors. Abbisko presented the following posters at the 2025 AACR: Title1: Preclinical Evaluation of ABSK112, a Selective and CNS-penetrant Compound with Strong HER2 Inhibitory Activity for Treating HER2-Driven Solid Tumors Session Category: Late-Breaking Research:

More news about: Abbisko


Apr 27, 2025, 21:00 ET ImmVira Presented Clinical Results of Oncolytic Product MVR-C5252 Targeting Malignant Glioma via Convection-Enhanced Delivery at 2025 AACR Annual Meeting

in collaboration with Duke University, a renowned institution with expertise in oncolytic virotherapy, immunotherapy, and CNS treatments. Unlike the commonly used Ommaya reservoir, MVR-C5252 is delivered intracranially via convection-enhanced delivery ("CED"). This approach

More news about: ImmVira


Apr 25, 2025, 20:00 ET Innovent Announces NMPA Approval of Limertinib, a Third-generation EGFR TKI Collaborated with ASK Pharma, for the First-line Treatment of Lung Cancer

0.34–0.58; p < 0.0001). In patients with central nervous system (CNS) lesions at baseline, median CNS PFS was also significantly longer with limertinib (20.7 months vs. 7.1 months), corresponding to a 72% risk reduction for CNS progression or death (HR 0.28; 95% CI: 0.10–0.82; p = 0.0136),

More news about: Innovent Biologics


Apr 25, 2025, 10:16 ET Belay Diagnostics Announces US Commercial Launch of Summit™: Breakthrough CSF Testing for CNS Cancer Detection and Management

clinical validation encompassed 124 patients with primary and secondary CNS cancers across both common and rare phenotypes. Glioblastomas, gliomas, medulloblastomas, and astrocytomas were included for primary CNS cancers. For metastatic CNS cancers, cancers originating in the lung, breast, and diffuse large

More news about: Belay Diagnostics


Apr 24, 2025, 10:00 ET THE MULTIPLE SCLEROSIS ASSOCIATION OF AMERICA INVITES YOU TO THE 11TH IMPROVING LIVES BENEFIT IN SUPPORT OF THE MS COMMUNITY

SclerosisMultiple sclerosis (MS) is a disease of the central nervous system (CNS), which consists of the brain, optic nerves, and spinal cord. MS damages or destroys the protective covering (known as myelin) surrounding the nerves of the CNS and can potentially injure the nerves as well. This damage causes reduced

More news about: Multiple Sclerosis Association of America


Apr 24, 2025, 09:20 ET Suvoda and Greenphire Announce Completion of Merger

global clinical trial technology company specializing in complex, life-sustaining studies in therapeutic areas like oncology, central nervous system (CNS), and rare diseases. Founded in 2013 by experts in eClinical technologies, Suvoda empowers clinical trial professionals to manage the most urgent moments

More news about: Suvoda LLC; Greenphire


Apr 24, 2025, 08:00 ET Alcyone Therapeutics Announces Strategic Financing to Advance an Expanded Pipeline of Pediatric-Focused Precision Therapeutics for Severe Neurological Diseases

clinical-stage pipeline of precision CNS therapeutics with a program exhibiting promising safety and preliminary efficacy data and significant commercial potential as a first-in-class disease-modifying therapy."  CLN-301 is one component of Alcyone's diversified portfolio of CNS therapeutics, which also includes

More news about: Alcyone Therapeutics


Apr 24, 2025, 07:00 ET Corero Named Finalist for the 2025 Joseph C. Belden Innovation Award

Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, announced that it has been named a finalist for the 2025

More news about: Corero Network Security


Apr 24, 2025, 06:38 ET Dizal to Showcase Data in Hematologic Malignancies and Lung Cancer at ASCO 2025

developing them over the course of their disease. NSCLC patients whose disease progressed after 3rd generation EGFR TKI treatment often develop CNS metastasis and exhibit acquired EGFR resistance mutations. Preclinical data shows that DZD6008 demonstrates good safety

More news about: Dizal Pharmaceutical


Apr 23, 2025, 19:00 ET Argent BioPharma Enters Germany - Europe's Largest Market

regions. About Argent BioPharmaArgent BioPharma Ltd. (ASX: RGT) develops proprietary therapeutics targeting central nervous system (CNS) and autoimmune disorders using its Neuro-Immune Modulatory (NIM) platform. Lead assets include CannEpil®, CogniCann®, and CimetrA®, which are now entering

More news about: Argent BioPharma Ltd.


Apr 23, 2025, 16:15 ET Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma

component of the formulation. Warnings and Precautions Hemorrhage Serious or fatal hemorrhage events, including fatal CNS hemorrhages, associated with prolonged thrombocytopenia, have occurred with VYXEOS. The overall incidence (grade 1-5) of hemorrhagic events was 74% in

More news about: Jazz Pharmaceuticals plc


Apr 23, 2025, 10:28 ET Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting

for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with

More news about: Nuvalent, Inc.


Apr 23, 2025, 07:00 ET Corero Appoints Edison Group to Strengthen U.S. and International Investor Distribution

Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, today announced the appointment of

More news about: Corero Network Security


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.